Visnor
Generic Name
Vildagliptin 50 mg tablet
Manufacturer
Renata Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| visnor 50 mg tablet | ৳ 5.00 | ৳ 50.00 |
Description
Overview of the medicine
Vildagliptin is an oral antidiabetic drug used to treat type 2 diabetes mellitus. It belongs to the class of DPP-4 inhibitors that help control blood sugar levels.
Uses & Indications
Dosage
Adults
The recommended dose is 50 mg once daily or 100 mg once daily (taken as 50 mg twice daily). The maximum recommended daily dose is 100 mg.
Elderly
No dosage adjustment is required based on age for elderly patients.
Renal_impairment
For patients with severe renal impairment (eGFR < 30 mL/min/1.73m²) or end-stage renal disease requiring hemodialysis, the recommended dose is 50 mg once daily. No dosage adjustment is needed for mild to moderate renal impairment.
How to Take
Take orally with or without food. If taken twice daily, take one tablet in the morning and one in the evening.
Mechanism of Action
Vildagliptin selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which degrades incretin hormones (GLP-1 and GIP). By inhibiting DPP-4, Vildagliptin increases the levels of active incretin hormones, enhancing glucose-dependent insulin secretion from pancreatic beta-cells and reducing glucagon secretion from alpha-cells.
Pharmacokinetics
Onset
Within hours of the first dose, contributing to improved glycemic control.
Excretion
Mainly renal excretion (approximately 85% of the dose), with a smaller portion (approximately 15%) eliminated via feces.
Half life
Approximately 3 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations (Cmax) reached in 1.7 to 2.5 hours. Absolute bioavailability is 85%.
Metabolism
Primarily hydrolyzed; the main metabolite (LAF237) is pharmacologically inactive. Cytochrome P450 enzymes are not significantly involved.
Side Effects
Contraindications
- •Hypersensitivity to Vildagliptin or any of its excipients.
- •Severe hepatic impairment (ALT or AST > 3 times the upper limit of normal).
Drug Interactions
ACE Inhibitors
Increased risk of angioedema when co-administered with ACE inhibitors.
Thiazides, Corticosteroids, Thyroid products
May reduce the hypoglycemic effect of Vildagliptin due to their own hyperglycemic potential.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
Experience with overdose is limited. Symptomatic and supportive treatment is recommended. Vildagliptin is not dialyzable.
Pregnancy & Lactation
Not recommended during pregnancy and breastfeeding due to insufficient data on safety and efficacy in these populations. Use only if potential benefit justifies the potential risk to the fetus or infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, as indicated on the packaging.
Availability
Pharmacies, Hospitals
Approval Status
Approved by regulatory authorities
Patent Status
Generic available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
